Tactiva Therapeutics is an immuno-oncology company specializing in potent cancer immunotherapy using a dual T cell receptor approach. D, MBA: Founder, CEO & President, September 2005-Part-time CFO & CMO. There is a lack of candidates in Buffalo, noted Colpoys. Colpoys is a self-described commercial guy, not a scientist. A Buffalo native, he left around 1979, working and living around the world; he returned here in 2003 and has been here ever since. Tactiva Therapeutics, development stage immuno-oncology company with a unique approach to adoptive T-cell therapy, announced today it has secured a $35 million Series A financing and closed on the first tranche of the financing. Lyra Therapeutics (Watertown, MA; $6.3M SBIR) up 22% [Apr 8, 22] announced that it has entered into a securities purchase agreement to sell securities in a private placement that is expected to result in gross proceeds of approximately $100.5 million, before deducting offering expenses. 3052999.95 370060.6. development of personalized medicine as a key driver of the Buffalo life sciences ecosystem is Privacy Policy | Terms of Use, Innovative Engineering of Immune Cells for Potent Cancer Treatment, Targeting Cancer in a Specific, Efficient and Durable Manner. Sophie Alexander, Contributing Editor, Jinfo. Fire & Flower Holdings last traded at $3.49 on the TSX. . Email: support@tacfireinc.com. Information for this briefing was found via Sedar and the companies mentioned. He also served as the Executive Director of the Center for Immunotherapy at RPCI. We are thrilled to have this syndicate of investors as partners in that effort, Factiva: An Expert's View. CEO. Tactiva Therapeutics is working to develop the next generation of cancer immunotherapies by utilizing a new approach to cell therapy. The business is initally filed on January 19, 2016. BIG was formed to support the application of advanced analytics, provide access to genomic expertise, and health informatics support to improve efficiency and effectiveness of health care outcomes in collaboration with companies in the biomedical and healthcare industries. | JOHNSON - Timothy P. Age 55, of Sylvania, OH, formerly of Buffalo, NY, passed away Thursday, December 29, 2016; son of the late Mike (late Mary) Johnson; dear husband of Lora (nee Heitzhaus); Tactical Therapeutics Inc (TTI) is a privately funded, clinical stage company that has developed and patented a lead therapeutic Carboxyamidotriazole Orotate (CTO) (Pravitinib (TM)) for the orphan indication glioblastoma (GBM) (fewer than 200,000 or 1 in 1500 persons are affected) and for other refractory targets. Developer of a therapeutic drug intended to help with the treatment of glioblastoma (GBM). 5764713.9 682178.45 As CEO of Tactiva Therapeutics, the Buffalo-based biotechnology company, Matthew Colpoys finds himself with the potential to help make a significant difference in the areas economic landscape.The company recently announced a capital raise of $35 million, one of the largest venture capital investments in the citys history, and Colpoys is now preparing to . Other executives include Brent A. Moen, Chief Finanical Officer; Thomas F. O'Donnell, Chief Medical Officer and 19 others. Current ACTapproaches in immunotherapy focus primarily on developing anti-tumor CD8 T cell responses while overlookingthe critical role of helper CD4 T cells. IR Contact: That includes co-founder and CEO Matthew Colpoys, director of . Vice President and General Manager, Medtronic Care Management Services. Were delivering a process, not making a product., Every stepfrom the moment a patient sits down in the chair to have their blood drawn, to its shipping, processing, and re-shipping back to be infused back into themhas to be rigorously documented in terms of chain of custody, said Colpoys. Tactiva Therapeutics is an Immuno-Oncology Company Utilizing an Innovative Approach to Adoptive Cell Therapy. The DOS entity number is #4881210. Tactiva Therapeutics has identified a library of T cell receptors (TCRs) from both CD8 T cells (CD8-TCRs) and CD4 T cells (CD4-TCRs) that specifically recognize and attack cancer cells. Executive Summary. Niagara Frontier Publications. Tactiva Therapeutics, development stage immuno-oncology company with a unique approach to adoptive T-cell therapy, announced today it has secured a$35 millionSeries A financing and closed on the first tranche of the financing. application of advanced analytics, provide access to genomic expertise, and health informatics support . tactiva therapeutics fires ceo Operating Status Active. several solid tumor type cancer indications. Tactiva Therapeutics Secures $35 Million Series A Financing to Pursue Shares of the clinical-stage biotech Five Prime Therapeutics ( FPRX) are up by a jaw-dropping 364% in pre-market trading Wednesday morning. Dr. Koya received his M.D. His research focuses on the area of Cancer Gene Therapy and Immunotherapy. Founders Kunle Odunsi, Richard C. Koya. Tactiva Therapeutics is an immuno-oncology company specializing in potent cancer immunotherapy using a dual T cell receptor approach. To fund early clinical trials, Tactical Therapeutics has since raised capital from a number of philanthropically motivated individuals devoted to bringing the therapy to patients in need. Tactiva Therapeutics is developing Next Generation adoptive cell therapy (ACT) strategies that deliver lethal hits to cancer cells. Ashley (Tisdale) Reagor, PT, MSPT, ATC Treatment Philosophy By providing focused and individualized treatment plans, I strive to help patients regain their independence. Ypsi-based nonprofits receive county grants for community violence intervention. Founded Date 2016. Buffalo, NY 14203. info@tactivatherapeutics.com. Dr. Koya is Professor of Medicine at University of Chicago, Biological Sciences Division, Department of Obstetrics and Gynecology and at the University of Chicago Comprehensive Cancer Center, where he leads the cGMP Vector Development and Production. Dublin, April 01, 2021 (GLOBE NEWSWIRE) -- The "Automated and Closed Cell Therapy Processing Systems Market By Cell Processing Steps, Scale of Operations, End Users and Geographical Regions: Industry Trends and Global Forecasts, 2020 - 2030" report has been added to ResearchAndMarkets.com's offering. tactiva therapeutics fires ceo - smarco.id 2013N700N700AN700N700A Windows8.1 w The "Automated and Closed Cell Therapy TacFire Inc. 5670 Schaefer Ave. Suite K. Chino, CA 91710. Tactiva Therapeutics utilizes a unique class of CD4 T cells that not only enhance the anti-tumor function of CD8 T cells, but also exhibit a capacity to directly target the tumor cells. Presented at the Virtual BioNJ Partnering Conference, October 6-7, 2020 The firm posted a loss for the fiscal year of $63.6 million. He believes that by fall of 2019, theyll have a good signal of where we stand with FDA, and hopes to be in a strong position to do an initial public offering in early 2020. Likes: 597. Advancing the development of personalized medicine as a key driver of theBuffalolife sciences ecosystem is an important focus of the BIG initiative," saidChristina Orsi, University at Buffalo Associate Vice President, Economic Development. Buffalo, NY based Tactiva Therapeutics, Inc. announced they've licensed new intellectual property from the Roswell Park Cancer Institute Corporation that covers the use of the Oncolytic Vaccinia Virus (OVV) armed with a CXCR4 antibody. Turning a patient's own cells into cancer fighters For those interested in Technology and Economic activity in Upstate NY All Rights Reserved. Tailored Therapeutics | VentureRadar When expanded it provides a list of search options that will switch the search inputs to . Dr. Zhang is the co-founder & CEO of TriArm Therapeutics, and is a Venture Partner of Panacea Venture. Andrew M. Cuomos Facebook Instagram. In CAR-T, we are striving for dramatically greater access to treatments by producing them from universal donor cells an off-the-shelf approach that will expand capacity and increase access while lowering costs. In addition, the company receives some funding from the universitys Center for Advanced Technology in Big Data and Health Sciences. Letrs Which Characteristics Describe Typical Outcome Assessments? ACEA Therapeutics is committed to developing and delivering innovative treatments to improve the lives of patients with life-threatening diseases. Turning a patient's own cells into cancer fighters - Department of All rights reserved. These startup drone companies will participate in the year-long program and will compete for a total of $3 million in direct investment, with one grand prize of up to $1 million and four There is an unmet medical need for treatment as the current prognosis is only 8.7% of patients surviving two years. Big Data and Health Sciences, which supported a collaboration that aids the companys Wilsons disease is a rare autosomal recessive disorder caused by a mutation in the ATP7B gene. Ms. Powell joined Tavanta Therapeutics in September 2019 and has 30 years of experience in the biopharmaceutical/ biotechnology industry. 225436398 27325623.75. Location: Orchard Park, NY. Current ACT approaches in immunotherapy focus primarily on developing anti-tumor CD8 T cell responses while overlooking the critical role of helper CD4 T cells. Privacy Policy | Terms of Use, Tactiva Therapeutics is an Immuno-Oncology Company Utilizing an Innovative Approach to Adoptive Cell Therapy. SAN JOSE, Calif., Nov. 14 /PRNewswire/ -- Tacere Therapeutics, Inc., an innovative biotechnology company specializing in the development of RNAi therapeutics to treat serious infectious diseases, announced today that Linda B. Couto, Ph.D., has joined as Vice President, Research and Development. Legal Name Tactiva Therapeutics, LLC. I believe [] I was born and raised in Las Vegas, Nevada. Tactiva Therapeutics LLC - Company Profile and News Tactical Therapeutics, Inc. Tactile Medical (NSDQ: TCMD) this week appointed Daniel Reuvers as president and CEO, effective June 8. Dr. Zhang is the co-founder & CEO of TriArm Therapeutics, and is a Venture Partner of Panacea Venture. Tactiva Therapeutics CEO Matthew Colpoys. Spotlight More. discovery efforts. See More July 10, 2012 -- Wilson Therapeutics AB (Wilson) has acquired Decuprate from Tactic Pharma LLC. has large experience in Executive roles in Biopharma. Tactiva Therapeutics | About Us May 22, 2020 By Danielle Kirsh. a potent therapeutic response with an ability to control metastatic growth and reverse the Contact Email info@tacerebio.com. Need Data? Shares: 299. Tactical Therapeutics, Inc. We believe it can have a meaningful impact on the lives of patients with cancer, and look forward to working closely with them to move their clinical programs forward to fulfill that promise. Tactile Medical (NSDQ: TCMD) this week appointed Daniel Reuvers as president and CEO, effective June 8. What happens next? tactiva therapeutics fires ceospinning top toy 70s. The entity type is . Dr. Koya was previously at Roswell Park Cancer Institute in Buffalo, NY, where he was Associate Professor of Oncology, Associate Director of the Center for Immunotherapy and the Director of the Vector Development and Production Facility. Tactiva projects adding 45 new employees inBuffalo. | JOHNSON - Timothy P. Age 55, of Sylvania, OH, formerly of Buffalo, NY, passed away Thursday, December 29, 2016; son of the late Mike (late Mary) Johnson; dear husband of Lora (nee Heitzhaus); The DOS ID is 5123211. The company's drug includes a novel, orally-administered small molecule that is a First-in-Class non-voltage Calcium Signal inhibitor and inhibits angiogenesis, metastasis, and tumor cell proliferation by addressing Other executives include Brent A. Moen, Chief Finanical Officer; Thomas F. O'Donnell, Chief Medical Officer and 19 others. 2013N700N700AN700N700A Windows8.1 w Prior to Tavanta she served as Chief Commercial Office at BioCryst, an emerging biotechnology company focused on commercializing innovative small molecules for rare diseases. Tavanta Therapeutics is a clinical stage specialty pharmaceutical company developing a broad pipeline of specialty drugs for patients with high unmet needs. But our industry needs tremendous amounts of capital. 5764713.9 682178.45 Use the PitchBook Platform to explore the full profile. Phone (212) 651-9653. Matthew Colpoys, CEO of Tactiva Therapeutics, remarked, This investment will allow us to Likes: 597. Roswell announces new Biotech Spinoff Company - WKBW Ashley (Tisdale) Reagor, PT, MSPT, ATC Treatment Philosophy By providing focused and individualized treatment plans, I strive to help patients regain their independence. Home All Products Optics Hand Guards New Arrivals. At Poseida, were harnessing the power of the immune system to develop safer, more effective, accessible, and affordable treatments. This type of personalized cancer treatment enhances the patient's immune system ability to tackle the disease. Built on a dual enhanced adoptive cell therapy (DEACT) platform, the company's engineered CD4/CD8 cells generate a durable supply of CD4 cells with direct anti-tumor . Sheri L. Dodd. The mindset here doesnt understand this industrys massive dilution. TACTIVA THERAPEUTICS, INC. is corporation filed with the New York State Department of State (NYSDOS). Tactiva Therapeutics is a Private company. Prior to Tavanta she served as Chief Commercial Office at BioCryst, an emerging biotechnology company focused on commercializing innovative small molecules for rare diseases. In CAR-T, we are striving for dramatically greater access to treatments by producing them from universal donor cells an off-the-shelf approach that will expand capacity and increase access while lowering costs. . Tactiva Therapeutics has identified a library of T cell receptors (TCRs) from both CD8 T cells (CD8-TCRs) and CD4 T cells (CD4-TCRs) that specifically recognize and attack cancer cells. Edit Lists Featuring This Company Section. Tactical Therapeutics Inc (TTI) is a privately funded, clinical stage company that has developed and patented a lead therapeutic Carboxyamidotriazole Orotate (CTO) (Pravitinib (TM)) for the orphan indication glioblastoma (GBM) (fewer than 200,000 or 1 in 1500 persons are affected) and for other refractory targets. With most chemical or biological products, youre just concerned about whether it works when you put it in humans. At Tactiva Therapeutics, we are taking the fight to cancer by developing Next Generation adoptivecelltherapy (ACT)strategies that deliver lethal hits to cancer cells. I love looking at good opportunities, Im interested in actively investing and trying to grow good opportunities here in Buffalo. His T-cell work has also led to spinoff activity: Tactiva Therapeutics LLC spun off in 2017, with Odunsi serving as chief medical officer. TacFire Inc. 5670 Schaefer Ave. Suite K. Chino, CA 91710. Preclinical data demonstrates cytotoxic function with CD4-TCRs, resulting in total tumor suppression when given by themselves. Shares of the clinical-stage biotech Five Prime Therapeutics ( FPRX) are up by a jaw-dropping 364% in pre-market trading Wednesday morning. Since launching in early 2017, Tactiva Therapeutics has leveraged the entrepreneurial James Huang, Managing Partner of Panacea Ventures, stated, "We are very excited by the potential of Tactiva's approach to TCR therapy. Portfolio Panacea Venture Tactical Therapeutics, Inc. Executive Summary. Tactiva TherapeuticsDEACT Unlike other intelligence solutions, BCIQ exclusively supports the unique needs of the biopharma industry and . Tactiva Therapeutics fires Buffalo-based CEO and staff. Use the CB Insights Platform to explore Tactiva Therapeutics's full profile. Presented at the Virtual 10 th World Orphan Disease Conference, August 24-26, 2020. CEO. The program . About Tactiva Therapeutics Tactiva is a development stage immuno-oncology company with a unique approach to adoptive T-cell therapy. This study provides a signal of the potency and durability of our proprietary CD4-TCR-engineered stem cells, said Matt Colpoys, Tactiva CEO. Roswell Park introduces "Tactiva Therapeutics" as new Biotech Spinoff Comapny. Kellen agreed to an initial investment higher than Colpoys asking amount. merrick okamoto net worth Use the PitchBook Platform to explore the full profile. Team Panacea Venture therapy. Tactiva's dual enhanced adoptive cell therapy (DEACT?) The firm has yet to get its expenses under control however, with SG&A amounting to $63.2 million, and total expenses coming in at $123.2 million. The Series A financing was led by PanaceaVentures and included Vi Ventures and Efung Capital. Phone (212) 651-9653. Glioblastoma (grade IV astrocytoma) is an aggressive primary brain tumor that is extremely difficult to treat. Tactiva Therapeutics has identified a library of T cell receptors (TCRs) from both CD8 T cells (CD8-TCRs) and CD4 T cells (CD4-TCRs) that specifically recognize and attack cancer cells. Buffalo, NY based Tactiva Therapeutics, Inc. announced theyve licensed new intellectual He is Co-Chair of the NCI Cancer Task Force of the Gynecological Cancer Steering Committee, and a member of the Institute of Medicine (IOM) Committee on The State of the Science in Ovarian Cancer Research. East Coast Startups (Top 10K) 9,912 Number of Organizations $203.3B Total Funding Amount 40,106 Number of Investors. Other executives include Brent A. Moen, Chief Finanical Officer; Thomas F. O'Donnell, Chief Medical Officer and 19 others. Rashida A. Karmali, JD, Ph. 225436398 27325623.75. The key activities now are to hire staff to analyze the existing data needed to prepare the investigational new drug application to file with the FDA. Tactiva Therapeutics Inc. - Company Profiles - BCIQ Tactiva Therapeutics has also received funding from the UB Center for Advanced Technology in Big Data and Health Sciences, which supported a collaboration that aids the company's discovery efforts. Fax (212) 651-9654 Management Team. 3053290.35 429071.5. current forms of TCR therapy in the treatment of solid tumors, including ovarian cancer. (Matt Uncategorized. He received a PhD from the University of Utah and did his post-doctoral training in Stanford University. Private Independent Company. All Rights Reserved. SAN JOSE, Calif., Nov. 14 /PRNewswire/ -- Tacere Therapeutics, Inc., an innovative biotechnology company specializing in the development of RNAi therapeutics to treat serious infectious diseases, announced today that Linda B. Couto, Ph.D., has joined as Vice President, Research and Development. We are thrilled to have this syndicate of investors as partners in that effort, and believe they bring an abundance of resources that will enable us to advance our programs on a global level.". Current ACT approaches in immunotherapy focus primarily on developing anti-tumor CD8 T cell responses while overlooking the critical role of helper CD4 T cells. I can do something elseafter you have a win, all of your next projects become easier. building a strong structure with index cards ohio obituaries this week In northside hospital gwinnett financial assistance ohio obituaries this week In northside hospital gwinnett financial assistance working to develop the next generation of cancer immunotherapies by utilizing a new approach to cell Dr. Tacere Therapeutics, Inc. specializes in the development of novel therapeutics for the treatment of serious infectious diseases such as Hepatitis C (HCV). We estimate that total sales of follow-on proteins and biosimilars will rise from $30 million in 2006 to $3.2 billion in 2011, which represents a market penetration of 2.7% across the board. All Rights Reserved. Personalize your news, get the . To get Tactiva off the ground, he talked to a potential investor, Michael Kellen, who is associated with the Cancer Research Institute, a prestigious New Yorkbased research and funding organization. Announces Appointment of a New Chief Executive Officer and New President of DRGT Research . July 10, 2012 -- Wilson Therapeutics AB (Wilson) has acquired Decuprate from Tactic Pharma LLC. Dr. Odunsi has implemented protocols for multi-institutional immunotherapy clinical trial under the NCI Cancer Immunotherapy Network (CITN) and the Cancer Vaccine Collaborative (CVC) of the Cancer Research Institute and Ludwig Institute for Cancer Research. Tactiva raises $35M in venture funding; successfully leverages life Recommended. 48 Wall Street, 12th Floor New York, NY 10005. Tactiva Therapeutics has identified a library Obalon Therapeutics. Presented at the Virtual BioNJ Partnering Conference, October 6-7, 2020 GENIUS NY, a business accelerator program at CenterState CEOs Tech Garden, announced the five finalists companies selected for its third round. tactiva therapeutics fires ceo. Tactiva Therapeutics, development stage immuno-oncology company with a unique approach to adoptive T-cell therapy, announced today it has secured a $35 million Series A financing and closed on the first tranche of the financing. Add Founded Year. About Tactiva Therapeutics Rashida A. Karmali, JD, Ph. Read more.. Former CFO of IDEV Technologies, ReAble Therapeutics and Cholestech Corporation. Tactical Therapeutics, Inc. Tactile Medical's President & Chief Executive Officer, Director is Daniel L. Reuvers. Tactiva Therapeutics, an immuno-oncology company and UB partner, is poised for growth in 2019. The address is 551 Franklin Street, Buffalo, NEW YORK 14202. Ms. Powell joined Tavanta Therapeutics in September 2019 and has 30 years of experience in the biopharmaceutical/ biotechnology industry. They will initiate a basket Entity Name. Need Data? It has 30 employees, up from 6 in 1987. tactiva therapeutics fires ceo. Since launching in early 2017, Tactiva Therapeutics has leveraged the entrepreneurial ecosystem that theUniversity at Buffalo(UB) and its partners inWestern New Yorkare working to grow. He previously was General Manager of Dragonboat Biopharmaceutical, and the Founding CEO of Dragon Sail Biopharmaceuticals. Tactiva Therapeutics Co-Founder Kunle Odunsi Elected to National Academy of Medicine, Tactiva Therapeutics Secures $35 Million Series A Financing to Pursue Clinical Development of DEACT Platform. Executive Summary. 2016 Tactiva Therapeutics. So, I agreed. We believe it can have a meaningful impact on the lives of patients with cancer, and look forward to working closely with them to move their clinical programs forward to fulfill that promise. Matthew Colpoys, CEO of Tactiva Therapeutics, remarked, This investment will allow us to Lists Featuring This Company. rhode island groundwater classification map. Dr. Koya is the author of many high-impact publications in the field of cancer research and currently leads NIH funded prospective clinical trials based on an immune-modulator-enhanced TCR-engineered T cell transfer for metastatic cancer patients. Activity from the CD4-TCRs augments the anti-tumor function of the Contact Email info@tacerebio.com. Vice President and General Manager, Medtronic Care Management Services. Tactiva Therapeutics is an Immuno-Oncology Company Utilizing an Innovative Approach to Adoptive Cell Therapy. tactiva therapeutics fires ceo 701 Ellicott Street, 4th Floor. Tactical Therapeutics Inc (TTI) is a privately funded, clinical stage company that has developed and patented a lead therapeutic Carboxyamidotriazole Orotate (CTO)(Pravitinib(TM)) for the orphan indication glioblastoma (GBM) (fewer than 200,000 or 1 in 1500 persons are affected) and for other refractory targets. Healthcare - Public. Dr. Dr. Koya has received many awards, including the Scholar Award from the Ministry of Education and Culture of Japan, the ITO Foundation, The Nickel-V Foundation and STOP CANCER Award. Tactiva Therapeutics, development stage immuno-oncology company with a unique approach to adoptive T-cell therapy, announced today it has secured a $35 million Series A financing and closed on the first tranche of the financing. Edit Lists Featuring This Company Section. Arcturus Therapeutics is a global late-stage clinical messenger RNA medicines and vaccines company focused on the discovery, development and commercialization of therapeutics for rare diseases and vaccines. Dr. Zhang is the co-founder & CEO of TriArm Therapeutics, and is a Venture Partner of Panacea Venture. one day be a valuable component in the eradication of this highly lethal disease. Tavanta Therapeutics Announces New Appointments to Strengthen its Executive and Senior Leadership Teams May 25, 2021 Tavanta Therapeutics Announces First Patient Dosed in Phase 3 Clinical Trial of TAVT-45 (abiraterone acetate) Granules for Oral Suspension, a Novel Formulation of Abiraterone Acetate, for the Treatment of Metastatic Prostate Cancer Chief Executive Officer. This type of personalized cancer treatment enhances the patient's immune system ability to tackle the disease. Arcturus Therapeutics is a global late-stage clinical messenger RNA medicines and vaccines company focused on the discovery, development and commercialization of therapeutics for rare diseases and vaccines. secured. The company's drug includes a novel, orally-administered small molecule that is a First-in-Class non-voltage Calcium Signal inhibitor and inhibits angiogenesis, metastasis, and tumor cell proliferation by addressing Developer of a therapeutic drug intended to help with the treatment of glioblastoma (GBM). Yohji Yamamoto() 20ss yohjiyamamoto . Mr. Harkey was Co-Founder and investor in CerSci Therapeutics, Inc., which was acquired by Acadia Pharmaceuticals, Inc. (NASDAQ:ACAD) in 2020 for up to $940 million. Our approach provides robust and sustained immuneattack on tumorsbyinfusing large numbers of patients own T cellsthat have been re-programed torecognize, attack and destroycancer cells. Part of Gov. As CEO of Tactiva Therapeutics, the Buffalo-based biotechnology company, Matthew Colpoys finds himself with the potential to help make a significant difference in the areas economic landscape.The company recently announced a capital raise of $35 million, one of the largest venture capital investments in the citys history, and Colpoys is now preparing to Company Type For Profit. Sheri L. Dodd. Tactical Therapeutics General Information Description. Proceeds of the financing will be used to advance the clinical development of Tactiva Therapeutics' dual enhanced adoptive cell therapy (DEACT) platform for the treatment of Multiple Myeloma and several solid tumor type cancer indications. Tacere Therapeutics, Inc. specializes in the development of novel therapeutics for the treatment of serious infectious diseases such as Hepatitis C (HCV). The Series A financing was led by Panacea Ventures and included Vi Ventures and Efung Capital. 2016 Tactiva Therapeutics. We need a win to show how it works., That win, he admits, is a long shot. Thats a major focus of the FDA review: Can we make it and deliver it with total control?.